Cumberland Pharmaceuticals announced a $100 million strategic transaction with Apotex Inc., selling its portfolio of FDA-approved brands to focus on developing orphan drug candidates addressing unmet medical needs. The deal, pending shareholder approval, aims to unlock shareholder value and support Cumberland's transition to a development-stage biopharmaceutical company. Cumberland's pipeline includes promising clinical programs for ifetroban, targeting rare diseases like Duchenne muscular dystrophy, systemic sclerosis, and pulmonary fibrosis, with recent FDA Fast Track designation for DMD. The company reported $9.1 million in Q1 2026 revenue and a net loss of $3.3 million, reflecting its shift towards innovation and development.
Asset Workflows Ltd, a UK-based asset data management firm, received a major strategic investment led by CoMade and two healthcare investors. This funding will accelerate its expansion in Australia and the Asia-Pacific region, enhance product develop...
Talk of a Tesla-SpaceX merger is intensifying as Elon Musk moves closer to taking SpaceX public. The two companies already share engineering talent and collaborate on energy, computing, and infrastructure challenges. The potential deal is largely dri...
TIFIN.AI has launched TIFIN Australia, a new joint venture aimed at bringing advanced AI technology to the Australian wealth management market. Led by experienced executives Marcus Price and Justin Schmitt, the platform will offer AI-native solutions...
Agora, Inc. announced its Q1 2026 financial results with revenues rising 13.5% to $37.7 million and net income increasing to $1.1 million, marking its sixth consecutive quarter of GAAP profitability. The company launched Agent Studio, a no-code platf...
Webco Industries reported a net income of $8.0 million for Q3 fiscal 2026, up from $5.0 million the previous year, driven by a 15.6% increase in net sales to $179.6 million. The company also saw improved gross profit margins and increased operating i...
